Benefits of Ixekizumab in Moderate-to-severe Plaque Psoriasis Patients

Dear Dr. Renukaprasad A R, There is an unmet need in the treatment of psoriasis to develop a better therapeutic regimen that has a rapid onset of action resulting in complete clearance of skin lesions. Ixekizumab, an anti-interleukin 17A (IL-17A) antibody, demonstrated rapid onset of action and significant improvement in the clearance of skin lesions in moderate-to-severe psoriasis patients. Eli Lilly brings together well-known dermatology experts, Dr. Krupa Shankar, Dr. Manas Chatterjee, and Dr. S G Parasramani, for discussing their clinical experiences followed by a panel discussion on the effective use of Ixekizumab in moderate-to-severe plaque psoriasis patients. Join us TODAY at 8:30 PM IST. Looking forward to your active participation in this informative discussion! Session highlights: Introduction and a brief overview of Ixekizumab prescribing information Ixekizumab in psoriasis: Putting evidence into clinical practice Is Ixekizumab just another IL-17 inhibitor? Panel discussion: Understand from the Experts about Ixekizumab Join Now Docplexus is one of the world's largest online communities Pune - 411045, India info@docplexus.co.in�� |� +91 98500 36954 You are receiving this communication because you are registered member of Docplexus. Unsubscribe from this mailing list. *|LIST:DESCRIPTION|* *|LIST:ADDRESS|* *|REWARDS_TEXT|*